Ipilimumab (Yervoy): Uses, Cost and Why It Is Combined
Ipilimumab, sold as Yervoy, is a CTLA-4 immune checkpoint inhibitor given by intravenous infusion. It is the odd one out among checkpoint inhibitors: it works at a different point in the immune response, it is given for a fixed short course rather than continuously, it is almost always paired with a PD-1 medicine rather than used alone, and it carries markedly more immune-related toxicity than a PD-1 medicine on its own.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
What does ipilimumab do differently from other immunotherapy drugs?
Ipilimumab releases a different brake, at an earlier point. Pembrolizumab, nivolumab and the PD-L1 medicines free T cells that have already reached the tumour. Ipilimumab blocks CTLA-4, a checkpoint that acts in the lymph nodes while T cells are first being switched on.
The distinction is worth understanding, because it explains almost everything else about this medicine. CTLA-4 is a molecule that appears on the surface of a T cell soon after it is activated. It competes with a stimulatory receptor called CD28 for the same partner on antigen-presenting cells, and when CTLA-4 wins that competition the T cell response is damped down. This happens at the priming stage, in the lymph node, before the T cell has reached a tumour at all. Ipilimumab is a fully human IgG1 antibody that binds CTLA-4 and removes that damping signal.
PD-1 and PD-L1 blockade works later and more locally, at the effector stage, inside the tumour itself. So the two are not stronger and weaker versions of the same thing. One widens the pool of T cells that get activated; the other stops the tumour from switching off the T cells that arrive. That difference in where each acts is also the reason the two are combined, the reason ipilimumab is given as a fixed short course, and the reason its side effects are broader.
| Ipilimumab (anti-CTLA-4) | Pembrolizumab, nivolumab (anti-PD-1) and the PD-L1 medicines | |
|---|---|---|
| Checkpoint blocked | CTLA-4, on the T cell | PD-1 on the T cell, or PD-L1 on the tumour cell |
| Where it acts | Lymph nodes, at the priming stage | Inside the tumour, at the effector stage |
| What it changes | Widens the pool of T cells that get activated | Keeps activated T cells working once they reach the tumour |
| Usual pattern of use in India | Almost always with a PD-1 medicine; rarely alone | Frequently alone, or with chemotherapy |
| Duration | Fixed short induction course, commonly four doses | Continued while working and tolerated, or to a defined ceiling |
| Immune-related toxicity | Higher, and broader across organ systems | Lower, though still real and sometimes serious |
| Indian biosimilar | None as of August 2026 | Nivolumab has one; the others do not, as of August 2026 |
A general orientation to the class, not a suitability comparison. Which medicine applies to a given patient is set by cancer type, stage, prior treatment and biomarker results, and only the treating oncologist can make that call.
Why is ipilimumab given with a PD-1 drug and not on its own?
Because the two act at different stages of the same immune response. Ipilimumab prompts more T cells to be activated in the lymph nodes. The PD-1 medicine keeps those T cells working once they reach the tumour. Ipilimumab used alone is now uncommon in Indian practice.
When ipilimumab was first approved internationally in 2011, it was used as a single agent in advanced melanoma. Practice has moved since. The indications put before India’s regulator in recent years have been combination indications, and the pattern on Indian prescriptions is the same — a CTLA-4 medicine added to a PD-1 medicine for a specific cancer at a specific stage, rather than chosen instead of one.
Two things follow from that, and both are worth saying plainly. First, dual blockade is not a general upgrade. It is used where an approved label and a guideline define a role for it, and adding it outside those settings adds toxicity and cost without a defined benefit. Second, being offered a PD-1 medicine on its own is not being offered a lesser treatment — in many cancers, single-agent blockade is exactly what the guidelines specify.
On the Indian regulatory position: ipilimumab is approved for a defined and narrow list of indications rather than for cancer in general. In November 2025 the CDSCO Subject Expert Committee for oncology reviewed and recommended approval of two additional indications for the 50 mg/10 mL presentation marketed by Bristol Myers Squibb India, both in combination with nivolumab: unresectable or metastatic melanoma, and first-line treatment of unresectable or metastatic hepatocellular carcinoma. An expert-committee recommendation is a step in the process and the licensing position continues to move, so the current approved indication for any individual diagnosis should be confirmed with the treating oncologist or the hospital pharmacy.
Approval in one cancer type says nothing about another. A cancer that is not on the approved list is not an off-label option a patient can request, and dual checkpoint blockade in particular is not something to seek out by name.
Why is toxicity higher with ipilimumab?
Because CTLA-4 sits earlier in the immune response, so blocking it lifts a restraint on T cells broadly rather than mainly around the tumour. More T cells are switched on, in more places. That is the intended effect, and it is also why healthy organs are inflamed more often.
In the advanced-melanoma trials that compared them directly, severe grade 3-4 treatment-related side effects were reported in roughly three in five patients on the combination, against roughly one in five on the PD-1 medicine alone, as summarised in NCCN and ESMO melanoma guidance. Those figures are indicative, as of August 2026, and they describe trial populations rather than any individual person. Lower ipilimumab doses on some schedules are associated with a lower rate than that. The direction of the difference, though, is consistent: adding CTLA-4 blockade adds risk.
What that means in practice is more monitoring, more steroid courses, more treatment stopped early for toxicity, and more hospital admissions than with a PD-1 medicine alone. It also means one specific risk that is more characteristic of CTLA-4 blockade than of any other checkpoint inhibitor: inflammation of the pituitary gland, which can leave a person needing hormone replacement for life. Thyroid and adrenal damage carry the same permanence. This is the reason the toxicity conversation matters more for this molecule than for any other in the class, and it deserves a proper discussion with the treating team before the first dose, not after the second.
| Organ affected | Typically starts | What it can look like |
|---|---|---|
| Skin | Earliest — often within the first two to three weeks | Rash, itching; occasionally severe blistering |
| Gut (colitis) | Commonly weeks 4 to 8, but any time | Loose motions increasing in number, abdominal pain, blood or mucus |
| Liver (hepatitis) | Commonly weeks 6 to 12 | Usually silent at first and picked up on blood tests; later, yellowing of eyes or skin |
| Thyroid | Weeks to a few months | Fatigue, weight change, feeling cold or unusually hot; often blood-test findings first |
| Pituitary (hypophysitis) | Often weeks 8 to 12, and more associated with CTLA-4 blockade | Persistent headache, severe fatigue, nausea, visual disturbance, low blood pressure |
| Adrenal glands | Any time, including after treatment ends | Collapse, vomiting, dizziness, profound weakness — a medical emergency |
| Lungs (pneumonitis) | Any time; often later in a course | New or worsening breathlessness, persistent dry cough |
| Heart muscle (myocarditis) | Rare, usually early — within the first six weeks | Chest pain, palpitations, breathlessness — a medical emergency |
Symptoms that need urgent assessment, not home management: loose motions that increase in number or contain blood; new or worsening breathlessness, or a persistent dry cough; chest pain or palpitations; persistent headache with nausea or visual change; severe unexplained fatigue with dizziness, vomiting or collapse; yellowing of the eyes or skin. For any of these, contact your treating oncology team immediately or go to the nearest emergency department. Do not self-medicate, and do not wait for the next scheduled cycle. Tell any doctor who sees you, in any department, that you are on checkpoint inhibitor immunotherapy — it changes how these symptoms are investigated and treated.
Timings above are indicative patterns described in NCCN and ESMO immune-toxicity guidance, as of August 2026. Immune-related events do not follow a schedule, and some appear weeks or months after the final dose. This page is an orientation to the medicine, not a triage tool.
Who ipilimumab is not for
Most people who search this drug name are not candidates for it. Ipilimumab has a narrower place in Indian oncology than any other checkpoint inhibitor, and its risk profile means the bar for using it is higher, not lower. It is generally not used, or is used only with specialist caution, in these situations:
- Cancers with no approved dual-blockade indication — if your diagnosis is not one of the settings where adding a CTLA-4 medicine has a defined role, it is not an option that can be requested.
- Situations where a PD-1 medicine alone is the recognised option — adding ipilimumab there adds toxicity and cost without a defined benefit.
- Active autoimmune disease needing systemic immunosuppression — releasing an immune brake this early in the response can worsen it, and CTLA-4 blockade does so more readily than PD-1 blockade.
- Solid-organ transplant recipients on anti-rejection medicines — there is a real risk of graft rejection.
- People already on high-dose steroids for another condition — this needs individual assessment before any decision is made.
- Existing pituitary, adrenal or thyroid disease — particularly relevant for this molecule, because these are the glands it most characteristically inflames.
- Significant existing lung or bowel inflammation — pneumonitis and colitis are among the events that become both more frequent and more severe with combination treatment.
- Poor overall performance status, or where close monitoring is not practical — this regimen assumes prompt access to blood tests, review and, if needed, admission. Where that access is not realistic, the risk calculus changes.
- Pregnancy — weighed carefully against any expected benefit.
It is also not an immunity booster, not a preventive, and not something to add to a plan without telling the treating team. Eligibility can only be decided by your own oncology team from your own reports, scans and treatment history.
How is ipilimumab given, and for how many doses?
Ipilimumab is given as an intravenous infusion in a day-care oncology unit, over about 30 minutes. It is given for a fixed short induction course — commonly four doses three weeks apart — after which the PD-1 medicine usually continues alone. It is not a tablet and it cannot be taken at home.
The fixed course is one of the most useful things to understand about this prescription, and one of the most often missed. Unlike a PD-1 medicine, which may run for many months, ipilimumab has a defined end point built into the regimen. In the combination used in advanced melanoma, ipilimumab is dosed at 3 mg/kg with nivolumab at 1 mg/kg every three weeks for four induction doses, and nivolumab then continues as maintenance on its own. Other settings use a lower ipilimumab dose, commonly 1 mg/kg, on a three-weekly or six-weekly schedule for a defined period. Your own protocol is set by your oncologist from the approved indication, and the schedule on your chart is the one that applies.
- Before each cycle — blood tests check thyroid, liver, kidney, cortisol where indicated, and blood-count values, and you are asked about new symptoms since the last visit. A delayed cycle because of a blood result is routine with this combination, not a setback.
- Review — the oncologist confirms it is safe to proceed that day. With dual blockade this review is more searching than with a single agent, and it should be.
- The infusion — a cannula is placed and the drug runs in over about 30 minutes. Where both medicines are given on the same day, they are given sequentially in the order the protocol specifies.
- Short observation — a period of monitoring for infusion reactions before you leave. Most people go home the same day.
- Between cycles — you watch for new symptoms and report them promptly. Immune-related effects can appear weeks or months after a dose, and after the induction course has finished.
- After the fourth dose — ipilimumab stops. Maintenance with the PD-1 medicine, if that is the plan, continues on its own schedule, and monitoring continues with it.
Treatment can also stop earlier — for disease progression, for a serious immune-related event, or because the person decides to stop. Stopping is a legitimate decision, not a failure, and with this combination it is a conversation that comes up more often than with single-agent treatment.
What does ipilimumab (Yervoy) cost in India?
Ipilimumab is among the most expensive checkpoint inhibitors per vial in India, and it has no Indian biosimilar. Published Indian distributor and pharmacy listings for the 50 mg vial sat in a wide band of roughly ₹60,000 to ₹80,000 when checked in August 2026. What is actually paid depends on body weight, the number of vials a dose needs, and the partner medicine.
Two features of this molecule pull the arithmetic in opposite directions, and both need to be in the estimate. Against the patient: dosing is by body weight, the drug is imported, no domestic version exists to bring the price down, and every induction cycle also carries the cost of the PD-1 medicine given alongside it. In the patient’s favour: the course is capped, usually at four doses, so unlike a medicine given continuously for a year, the ipilimumab component of the bill has a visible ceiling from the start.
| Cost element | What it depends on | Published reference point (indicative, as of August 2026) |
|---|---|---|
| Drug — 50 mg/10 mL vial | Number of vials per dose, set by body weight | Indian distributor and pharmacy listings in a wide band of roughly ₹60,000 to ₹80,000, with individual listings reported outside that band in both directions |
| Drug — 200 mg presentation | Whether the larger vial is stocked and used | Reported in published Indian price comparisons at roughly ₹2.6 to ₹3.2 lakh per vial |
| Dose schedule | Approved indication and body weight | Commonly 3 mg/kg every three weeks in the melanoma induction regimen; 1 mg/kg on some other schedules |
| Number of doses | Regimen, response and tolerance | Usually capped at four induction doses — the ceiling that distinguishes this molecule from continuously given medicines |
| The partner PD-1 medicine | Which molecule, and for how long after induction | Costed separately and usually the longer-running half of the bill; nivolumab has had an Indian biosimilar since January 2026, ipilimumab has none |
| Managing side effects | Whether an immune-related event occurs, and how severe | Steroid courses, extra reviews and occasional admission — the cost most often left out of an estimate, and materially more likely with dual blockade |
| Day care, nursing, pre-cycle blood tests | Each visit | Billed by the treating centre, separately from the drug |
| Response-assessment imaging | Scan interval set by the oncologist | Usually coordinated at a partner imaging centre and billed separately from treatment |
Those are third-party published listings, checked in August 2026, quoted so the arithmetic is visible. They are not a hospital rate for this molecule, and no rate for it is quoted on this page. Listings for imported oncology antibodies vary widely between retail pharmacies, hospital pharmacies and distributors, and all of them move. Ask for a written, itemised estimate covering the full induction course and the maintenance phase before the first cycle, and ask separately what a state scheme, CGHS, ECHS or your insurer will and will not cover — high-cost immunotherapy is frequently capped or excluded, and a scheme ceiling set for a protocol does not automatically stretch to a dual-blockade regimen. A wider molecule-by-molecule view sits on the immunotherapy cost comparison across all drugs.
Ipilimumab (Yervoy): Frequently Asked Questions
What does ipilimumab (Yervoy) do differently from pembrolizumab or nivolumab?
It releases a different brake, at an earlier point. Pembrolizumab and nivolumab block PD-1, which frees T cells that have already reached the tumour. Ipilimumab blocks CTLA-4, a checkpoint that acts in the lymph nodes while T cells are first being switched on. The practical consequence is that ipilimumab widens the pool of activated T cells rather than releasing the ones already in place. That is also why it is given as a fixed short course rather than continuously, and why its side-effect profile is heavier.
Why is ipilimumab given with a PD-1 drug instead of on its own?
Because the two act at different stages of the same immune response. Ipilimumab prompts more T cells to be activated in the lymph nodes. The PD-1 medicine keeps those T cells working once they reach the tumour. In current Indian and international practice ipilimumab on its own is uncommon, and the indications recently put before the CDSCO expert committee were combination indications with nivolumab. Dual blockade is defined by an approved label and a guideline for a specific cancer and stage. It is not a general upgrade a patient can request by name.
Why is toxicity higher with ipilimumab than with a PD-1 drug alone?
Because CTLA-4 sits earlier in the immune response, so blocking it lifts a restraint on T cells more broadly rather than mainly around the tumour. In the advanced-melanoma trials that compared them directly, severe grade 3-4 treatment-related side effects were reported in roughly three in five patients on the combination against roughly one in five on the PD-1 medicine alone, as summarised in NCCN and ESMO melanoma guidance. Those figures are indicative, as of August 2026, and describe trial populations rather than any individual. Colitis, hepatitis and pituitary inflammation are all more frequent, and hormone damage can be permanent.
Is ipilimumab (Yervoy) approved and available in India?
Yes, for a defined and narrow list of indications rather than for cancer in general. Yervoy is marketed in India by Bristol Myers Squibb India. The CDSCO Subject Expert Committee for oncology recommended approval of two further indications in November 2025, both in combination with nivolumab: unresectable or metastatic melanoma, and first-line treatment of unresectable or metastatic hepatocellular carcinoma. Only the imported originator product is supplied, and no Indian ipilimumab biosimilar exists as of August 2026. Approved indication lists change, so confirm the current position for your exact diagnosis with your treating oncologist.
What does ipilimumab (Yervoy) cost in India?
Ipilimumab is among the most expensive checkpoint inhibitors per vial. Published Indian distributor and pharmacy listings for the 50 mg per 10 mL vial sat in a wide band of roughly 60,000 to 80,000 rupees when checked in August 2026, with 200 mg presentations listed at roughly 2.6 to 3.2 lakh. Those are third-party published figures, indicative, as of August 2026, and not a rate from any hospital. Dosing is by body weight, so the number of vials per dose varies, and day-care, blood-test and imaging charges are billed separately.
How many doses of ipilimumab are given?
Usually four, and then it stops. In the combination regimen used in advanced melanoma, ipilimumab is given with nivolumab once every three weeks for four induction doses, after which nivolumab continues alone as maintenance. Some other settings use a lower ipilimumab dose given every six weeks for a defined period. Each infusion runs over about 30 minutes in a day-care unit. That fixed short course is why a very high per-vial price does not translate into an open-ended cost the way a continuously given medicine does.